DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE | N210192 | VIIV HEALTHCARE CO
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
ViiV Healthcare Company et al v. Zydus Pharmaceuticals (USA) Inc. et al 2 patentsANDA 220907Dolutegravir Sodium/Rilpivirine Hydrochloride | D. Del. | 2025-12-17 | Active | — |
ViiV Healthcare Company et al v. Cipla Limited et al 2 patentsANDA 214607Dolutegravir Sodium/Rilpivirine Hydrochloride | D. Del. | 2020-07-22 | Terminated 2023-03-14 | — |
ViiV Healthcare Company et al v. Lupin Limited et al 2 patentsANDA 213120Dolutegravir Sodium and Rilpivirine Hydrochloride | D. Del. | 2020-02-28 | Terminated 2022-03-30 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$121.77
per ea
Lowest NADAC/Unit
$121.77
per ea
Brand NDCs
1
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 49702024213JULUCA 50-25 MG TABLET | $121.77 | EA | Brand | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.